Opthea (OPT) said Tuesday it has appointed Parisa Zamiri as its chief medical officer, effective Oct. 7, and Tom Reilly as its chief financial officer, effective Oct. 28.
Zamiri most recently served as Complement Therapeutics' medical chief while Reilly was previously the CFO of Amarin (AMRN).
The company said it is continuing to prepare for the phase 3 topline data readouts of its lead product candidate sozinibercept, with readouts from its COAST study anticipated in early Q2 2025 and from its ShORe trial in mid-2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.